Biostage Performance

The firm shows a Beta (market volatility) of 0.0, which signifies not very significant fluctuations relative to the market. the returns on MARKET and Biostage are completely uncorrelated.

Risk-Adjusted Performance

Weakest

Weak

Strong

Over the last 90 days Biostage has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable basic indicators, Biostage is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders. ...more

Biostage Relative Risk vs. Return Landscape

If you would invest (100.00) in Biostage on December 5, 2025 and sell it today you would earn a total of 100.00 from holding Biostage or generate -100.0% return on investment over 90 days. Biostage is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of otc stocks are less volatile than Biostage, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.

Expected Return

Risk

Biostage Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Biostage for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Biostage can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.

	Biostage is not yet fully synchronised with the market data
	Biostage has some characteristics of a very speculative penny stock
	Biostage has a very high chance of going through financial distress in the upcoming years
	Net Loss for the year was (7.98 M) with profit before overhead, payroll, taxes, and interest of 0.
	Biostage currently holds about 4.64 M in cash with (2.63 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.4.
	Roughly 51.0% of the company shares are held by company insiders

Biostage Fundamentals Growth

Biostage OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Biostage, and Biostage fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Biostage OTC Stock performance.

	Return On Equity	-4.92
	Return On Asset	-2.11
	Current Valuation	78.64 M
	Shares Outstanding	11.64 M
	Price To Earning	(0.16) X
	Price To Book	28.47 X
	EBITDA	(8.36 M)
	Cash And Equivalents	4.64 M
	Cash Per Share	0.40 X
	Total Debt	115 K
	Debt To Equity	0.04 %
	Book Value Per Share	(0.16) X
	Cash Flow From Operations	(2.63 M)
	Earnings Per Share	(0.89) X
	Total Asset	1.87 M
	Retained Earnings	(65.78 M)
	Current Asset	7.88 M
	Current Liabilities	654 K

Things to note about Biostage performance evaluation

Checking the ongoing alerts about Biostage for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Biostage help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.

	Biostage is not yet fully synchronised with the market data
	Biostage has some characteristics of a very speculative penny stock
	Biostage has a very high chance of going through financial distress in the upcoming years
	Net Loss for the year was (7.98 M) with profit before overhead, payroll, taxes, and interest of 0.
	Biostage currently holds about 4.64 M in cash with (2.63 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.4.
	Roughly 51.0% of the company shares are held by company insiders

Evaluating Biostage's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Biostage's otc stock performance include:

Analyzing Biostage's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Biostage's stock is overvalued or undervalued compared to its peers.
Examining Biostage's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
Evaluating Biostage's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Biostage's management team can help you assess the OTC Stock's leadership.
Pay attention to analyst opinions and ratings of Biostage's otc stock. These opinions can provide insight into Biostage's potential for growth and whether the stock is currently undervalued or overvalued.

It's essential to remember that evaluating Biostage's otc stock performance is not an exact science, and many factors can impact Biostage's otc stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in population.

You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.

Other Consideration for investing in Biostage OTC Stock

If you are still planning to invest in Biostage check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Biostage's history and understand the potential risks before investing.

	Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios.
	Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk
	Commodity Channel Use Commodity Channel Index to analyze current equity momentum
	Risk-Return Analysis View associations between returns expected from investment and the risk you assume
	CEOs Directory Screen CEOs from public companies around the world
	Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios
	Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments
	Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
	FinTech Suite Use AI to screen and filter profitable investment opportunities

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC